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Abstract
Genomics is now a core element in the effort to develop a vaccine against HIV-1. Thanks to
unprecedented progress in high-throughput genotyping and sequencing, in knowledge about genetic
variation in humans, and in evolutionary genomics, it is finally possible to systematically search the
genome for common genetic variants that influence the human response to HIV-1. The identification
of such variants would help to determine which aspects of the response to the virus are the most
promising targets for intervention. However, a key obstacle to progress remains the scarcity of
appropriate human cohorts available for genomic research.
Despite repeated exposures, some individuals do not seem to become infected with HIV-1, and
among those that do, there is marked variation in how the virus is handled and in the time-
course of progression to AIDS. It is known that host genetic differences contribute to this
variation, but our knowledge of the relevant host genetic factors is currently limited for two
main reasons: first, many studies have suffered from suboptimal study design, which is a
common theme in the genetic-association literature1; second, a limited number of host genes
have been studied so far, and these studies have focused heavily on candidate genes of acquired
immunity and on proteins implicated in molecular studies of HIV-1 cell entry and
proliferation2,3 (Table 1).
The candidate-gene approach is based on a priori knowledge of the role or potential role of a
gene in HIV pathogenesis. On selection of the candidate gene, the corresponding genomic
region can be genotyped at known polymorphic positions, or re-sequenced with the purpose
of identifying unknown variants. Association analysis can address the individual contributions
of any single nucleotide polymorphism (SNP), or of a series of linked SNPs represented by a
haplotype, to a study phenotype (Box 1). Statistical analysis needs to take into account issues
such as multiple testing that will lead to an increasing number of false-positive tests as the
number of SNPs, alleles, study endpoints, phenotypes or subgroups increase. Selected
candidate SNPs are then followed by dedicated genetic, functional and biological testing to
establish causality.
Despite important efforts by various research groups, the candidate-gene approach has yielded
limited results so far (Table 1). Only a fraction of the observed variability in the course of
HIV-1 infection is explained by current knowledge2,4. The reasons for the limited success of
this otherwise intuitively attractive hypothesis-driven approach is manifold, and include a
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limited knowledge of the attributes of candidate genes, lack of statistical power to detect small
effects, incomplete knowledge of the genetic variation of the region, the inherent complexity
of establishing the functionality of particular alleles and, until recently, the absence of efficient
genotyping technologies. However, an optimist might point out that although only a modest
number of genes have been assessed, and incompletely at that, there have nevertheless been
unambiguous discoveries of important gene variants. Notable among these are the highly
protective CCR5 Δ32 allele and the crucial role of selected human leukocyte antigen (HLA)
alleles in disease progression.
The impact of HIV-1 infection on human health, the rapidity of expansion of the global HIV-1
epidemic, and the limitations of the candidate-gene approach argue for an immediate adoption
of genome-wide association approaches. Here, genetic analyses assess the whole genome, or
large genomic regions, with the goal of identifying genes associated with susceptibility to
HIV-1, even in the absence of a priori knowledge of the most important genes. In this
Perspective article, we discuss the new opportunities in HIV-1 research that have arisen through
the development of high-throughput systems for SNP genotyping using information from the
International Haplotype Mapping Project (or HapMap), and the use of comparative genomics
to identify regions that are involved in host–pathogen genetic conflicts. Success in HIV-1 host
genomic studies will depend on several key steps, notably, the identification of appropriate
study phenotypes and the availability of large human cohorts for genetic studies5. The potential
to harness genomic information for vaccine design will rest on the nature of the genes and
alleles identified from the expected plethora of information emanating from host genomic
projects.
Genomic opportunities
The heritable nature of susceptibility to HIV-1 can be observed in the familial segregation of
a phenotype of resistance to infection, in studies of infected twins, and at the cellular level6–
9. A significant heritable component of a phenotype constitutes the basis for genome analysis.
Whole-genome studies can use data from families or from independent individuals; analysis
of families can track the transmission of susceptibility alleles through generations. This
approach, known as linkage analysis, is widely used in the mapping of monogenic disorders,
and uses a few hundred polymorphic markers throughout the genome to identify the
chromosomal region involved (for example, in rare familial syndromes of susceptibility to
infectious diseases)10. However, family approaches are not feasible in the field of HIV-1
because of the limited familial nature of HIV-1 exposure (except in the setting of mother to
child transmission). It is also known that family based approaches have limited power to detect
gene variants that influence complex traits11. Therefore, studies of susceptibility loci in HIV-1
infection rely on population-based cohorts, using a denser map of genetic markers (hundreds
of thousands) to do association studies between markers (such as SNPs) and the phenotype of
interest. Genome approaches can also use data from other species, in particular from primates
that show differences in the control of HIV-1 or of other lentiviruses, especially the simian
immunodeficiency virus (SIV). These approaches are discussed further below.
HapMap and genetic-association studies
Over the past few years there has been a remarkable increase in our knowledge of the variation
in the human genome and, today, most common human SNPs are known. In a particularly
important effort, the HapMap (Box 1) identified the minimum number of SNPs that are needed
to represent common human diversity. For this, the HapMap characterized patterns of
association among different gene variants — the patterns of linkage disequilibrium across the
genome — to select a minimal set of variants that are sufficient to represent common human
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variation in the context of an association study. These selected SNPs are referred to as tagging
(tag) SNPs12,13 (Box 1).
In parallel with this increased knowledge, genotyping technologies have advanced significantly
and now allow sufficient throughput to accommodate genome-wide approaches14. There is
now a set of commercial whole-genome arrays using tag SNPs that represent variation in the
human genome in non-African populations15,16. This means that the association of common
variation with HIV-1 susceptibility can now in principle be satisfactorily captured by using
sample sizes that are large enough to detect the effect of gene variants of modest impact. But
key constraints remain. For example, it is known that rare variants will not be well represented
in tagging strategies17. In addition, and of particular concern in the HIV-1 host genetics field,
the current platforms for whole-genome analysis are known to represent variation in Africa
inadequately. This asymmetry is both unfair and a constraint in HIV-1 genomics research and
will need to be addressed directly as a priority. Not only is HIV-1 infection extremely prevalent
in many parts of Africa, it is probable that there might be gene variants in Africa relevant to
HIV-1 that have allele frequencies that are different from other populations. This is because
of general patterns of population differentiation and possibly also because of recent
selection16. This means that some genetic variants might be easier to find in some African
populations in comparison with non-African populations and vice versa.
In Fig. 1, the design of a whole-genome association analysis of phenotypes with susceptibility
to HIV-1 is shown, using a tagging strategy based on HapMap data to represent variation in
the human genome. The design must take account of the known problems in the field. At the
stage of study design, these problems include the undefined influence of the environment, and
the difficulty of controlling for stratification, in particular linked to population or ethnic
substructuring of sample sets, which is often also confounded by socioeconomic factors that
influence infection and host response18. In addition, these studies present difficulties in
defining and achieving adequate power and in establishing the computational and statistical
analytical routines that are necessary to distinguish true- and false-positive discoveries and,
more generally, to prioritize candidate genes to be investigated using genetic and functional
approaches.
Use of the HapMap resource
The availability of commercial products for whole-genome association analyses means that
the use of the HapMap and other resources for genetic-association analyses has shifted from
the upstream tasks of selecting what SNPs to genotype to the downstream tasks of interpreting
the observed genotype–phenotype associations, and prioritizing the associations on the basis
of their likelihood of being real rather than chance associations. However, this transition has
occurred more rapidly than most researchers seem to have expected, and there are few tools
available that allow ready interpretation of the results of whole-genome association studies.
Considerable development is now needed to establish a framework for post-association
annotation that will allow convenient high-throughput assessment of all those SNPs that show
suggestive association with target phenotypes. Because real causal variants are likely to often
show associations of a magnitude similar to those that show association purely by chance
(because of the many polymorphisms that have been assessed) the degree of association for
each of the SNPs must be assessed relative to features such as proximity to exons, location of
conserved stretches of sequence and genomic regions with predicted regulatory function. The
HapMap project will be a key tool in interpreting association results by allowing researchers
to assess which polymorphisms are associated with the study phenotype (Box 1).
Ge and Goldstein have recently developed one tool for this purpose (see the Duke Institute for
Genome Sciences and Policy in Further information), that uses available databases to draw the
predicted gene structure, including sites of alternative splicing, and puts all the SNPs and their
Telenti and Goldstein Page 3
Nat Rev Microbiol. Author manuscript; available in PMC 2007 October 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
associated significance values onto this gene structure. Patterns of linkage disequilibrium
throughout the gene are also indicated using HapMap data. These gene diagrams can then be
used to identify the associations that seem most likely to be biologically relevant and can also
be used to determine which genomic regions need to be resequenced to identify the causal
polymorphisms that might be responsible for the association.
Comparative genomics
Just as humans differ in how well they handle HIV-1, non-human primate species differ in
their handling of related retroviruses19. These differences include: resistance to infection (for
example, differences in the susceptibility of primate cells to various lentiviruses)20,21; the
satisfactory control of viral replication when infected (for example, in most experimentally
infected chimpanzees, HIV-1 replicates poorly)22; and the occurrence of infections that are
characterized by high-level replication without the hallmarks of disease progression (for
example, in sooty mangabey and African green monkeys)23,24. One key observation is that
naturally infected African primates do not develop immunodeficiency and have lower levels
of T-cell immune activation and activation-induced cell death than HIV-1-infected humans.
Recently, Schindler et al. reported that differences in the accessory viral protein Nef among
primate lentiviruses (HIV compared with SIV) could explain the patterns of immune
activation25. Nef alleles of HIV-1 fail to downregulate the T-cell receptor CD3 from infected
cells thereby maintaining the responsiveness of infected T cells to activation25, in contrast to
SIVs that downregulate CD3. However, there are several apparent exceptions to this view, and
resolution of the role of Nef in immune activation awaits further investigation26.
Just as comparing the genomes of the various lentiviruses might explain important differences
in immune pathogenesis between humans and non-human primates, exploring differences in
the host genome can provide crucial insights into defence against retroviruses. Evolutionary
genomic approaches have been proposed as powerful tools to identify regions in host proteins
that are relevant for host–pathogen interactions27. These methods identify signs of positive
selection or negative selection in the genome. A recent report from Voight et al. presents a
map of recent positive selection in the human genome that shows the tremendous shifts
experienced by modern human populations in habitats, food sources and population
densities28. These signatures of selection are likely to be valuable signposts for gene variants
that might influence medically relevant traits, including the susceptibility to infectious diseases,
clearly one of the key selection pressures in human history. The availability of the complete
chimpanzee and Rhesus macaque monkey genomes, and the ease of cross-species sequence
amplification owing to the high degree of sequence conservation among humans and non-
human primates allows comparative host genome analyses.
The first applications of evolutionary genomics to the field of HIV-1 have shown remarkable
success. Comparative analysis of the primate antiretroviral cellular defence genes that encode
APOBEC3G and TRIM5α (discussed below) has revealed the powerful selective pressures
that have emerged from a long-standing battle between retroviruses and their hosts29–31.
These proteins belong to a newly described form of innate immunity, coined ‘intrinsic
immunity’, that assures protection by providing an ‘always-on’ line of defence, generally
through intracellular obstacles to the replication of pathogens32. This component of the
immune system is a cornerstone of the resistance of mammals against several classes of
retroelements and retroviruses32.
Primate APOBEC3B, 3C, 3F and 3G have antiretroviral activity associated with the
hypermutation of viral DNA through cytidine deamination (for recent reviews see Refs 21,
33). However, the best studied member in humans, APOBEC3G, fails to restrict HIV-1 owing
to degradation induced by the HIV-1 accessory protein virion infectivity factor (Vif)34. By
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contrast, several primate APOBEC3G proteins show activity against HIV-1 (Refs 21,35,36).
Analysis of APOBEC3G across primate species reveals many residues in the amino-terminal
cytidine deaminase domain that are under positive selection, which coincides with the proposed
region of interaction with Vif (Fig. 2). Analyses have also shown that amino-acid residue 128
is under positive selection, which fits with evidence that this amino acid discriminates among
the various HIV and SIV Vif proteins35,36.
The tripartite motif (TRIM) family is a large family of proteins that are characterized by a
structure comprising a RING domain, one or two B-box domains and a predicted coiled-coil
region37. In addition, TRIM proteins have specialized carboxy-terminal domains38,39. Some
TRIM proteins display antiviral properties that target retroviruses in particular20. The best
studied antiviral TRIM protein, TRIM5α, is a retroviral restriction factor that targets the early
steps of cellular infection20; TRIM5α specifically recognizes the viral capsid and promotes its
premature disassembly40. Human TRIM5α has limited efficacy against HIV-1, whereas some
primate TRIM5α proteins can potently restrict HIV-1 (for reviews see Refs 38,39). Analysis
of the TRIM5α protein across primate species pin-points a patch of amino acids that is under
positive selective pressure at variable 1 region (v1) and variable 2 region (v2) (Fig. 2). Chimeras
of human TRIM5α that carry the v1 patch from other primates, or selected mutants in the
variable regions, can restrict HIV-1 (Refs 41–44). The variable regions of TRIM5α might have
evolved independently to recognize various retroviruses44; however, in the absence of a crystal
structure of the molecule, the exact molecular mechanisms that underlie the evolutionary
changes remain undefined.
Comparative and evolutionary genomic methods have been applied to the understanding of
other components of innate immunity. These include the analysis of the vertebrate Toll-like
receptor proteins (an example of evolutionary conservation at multiple levels)45, the DC-SIGN
(CD209) family of C-type lectins46,47 and the KIR genes that encode the main functional
receptors of natural killer (NK) cells in humans, in whom the evolutionary forces driving the
genesis of NK receptors and their HLA ligands represent a concerted response to
pathogens48. Signals of evolutionary selection have also been searched for in 168 genes that
are related to immune function49.
One should expect evolutionary analysis to become routine in the initial assessment of proteins
that are involved in the pathogenesis of HIV-1 and SIV infection and of genes identified through
whole-genome association analysis. The identification of signs of positive selection and of
patches of genetic conflict should be a criterion for biological analysis. Therefore, there is great
interest in promoting the sequencing of whole genomes from many more primates. Importantly,
this effort should include our most distant relatives, the new world monkeys (such as tamarins),
and prosimians (such as lemurs), to provide the needed out group and reference to estimate the
evolutionary history of the proteins. However, as indicated in a recent review50, the flood of
data and analytical methods in evolutionary and comparative genomics raise many new
challenges, in particular the inherent multiple comparisons problem in searching the entire
genome for specific regions that show evidence of selection. This creates a large ‘opportunity
space’ for finding regions that show unusual patterns of variation in populations, or divergence
among species, and the appropriate methodologies to correct for the number of possible tests
that could be constructed are not obvious. Therefore, there is a need for the clear demonstration
of the usefulness of a series of new dedicated statistical tests, more rigorous demonstration of
evidence for natural selection and the inclusion of functional evidence for candidate loci50.
Phenotypes for genomic analysis
Most genetic studies so far have focused on endpoints, such as ‘time to AIDS or death’, that
represent complex phenotypes resulting from many potential influences. Studies have also
Telenti and Goldstein Page 5
Nat Rev Microbiol. Author manuscript; available in PMC 2007 October 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
compared infected individuals with individuals that remain HIV-1 free despite repeated
exposure; however, there is often limited accounting for the degree of exposure51. Least
satisfactory, many studies have compared the frequencies of certain alleles in the infected
population with the frequency in the general population, which is an insensitive measure of
the enrichment or depletion of a genetic variant that is putatively associated with susceptibility
to infection. Modest genetic influences on a disease will be hard to trace if masked by the
influences of environment or concurrent disease. Therefore, there is a pressing need for study
phenotypes that can be measured precisely, that are least influenced by external factors and
that best reflect the basic mechanisms of pathogenesis.
The most useful insights will come from studies that focus on specific aspects of the response
to HIV-1 that are sufficiently precise and narrow to guide our understanding of how the immune
system controls or fails to control the virus. The overall pattern of viral replication following
infection is one of an initial rapid increase to a peak level followed by the establishment of a
viral load set point (at which the level of viraemia remains constant), which persists for an
extended period, often many years (Fig. 3). Little is known about what determines peak viral
load or exactly how it relates to disease progression in humans. In the simian HIV-1 infection
model, there is a strong correlation between peak viral load and the extent of CD4+ T-cell
depletion during acute infection52. Up to 80% of CD4+ T cells are infected at peak viraemia
and the proportion of CD4+ T cells that are destroyed is correlated with the peak viral
load52. The simple relationship between viral load and CD4+ T-cell depletion could allow
prediction of the level of viral control that is required to prevent early immune damage.
However, it is difficult to capture the unique window of peak viraemia in human cohorts as it
requires a substantial effort in HIV-1 surveillance53.
Similarly, the level of viraemia at set point is a determinant of the natural history of SIV
infection54 and of the long-term prognosis of HIV-1 infection in humans55. The viral load set
point is a particularly attractive target as a study phenotype. First, it is known that individuals
vary by several orders of magnitude in the amount of virus per ml of blood at set point8, as
illustrated in Fig. 3. For instance, there are rare individuals whose set point is at a level of virus
that is essentially not detectable56. Second, the viral load set point is a characteristic of the
individual. So far, there have been no large-scale genomic studies to determine the source of
this variation. The identification of gene variants that are associated with the variation in viral
load set point could implicate particular aspects of immune control. Peak and set-point viraemia
are also of direct interest because they predict the degree of infectiousness of the
individual57.
The fact that the viral load set point is established so early in the course of HIV-1 infection and
that it seems to be particularly resistant to external variants over prolonged periods suggests
that the environment might be only a small contributor. Therefore, the viral load set point seems
to be determined mainly by two variables: influences from the host genome and the viral strain
genome. Of course it cannot be ruled out that early environmental factors in an individual's
life affect his or her immune system in such a way as to influence the set point that will be
established on infection.
Another phenotype of significant interest for genetic studies is the status of exposed non-
infected individuals. Indeed, the first identified gene variant that influenced susceptibility to
HIV-1, CCR5 Δ32 was discovered using this framework. Several studies have examined
heterosexual couples that are discordant for HIV-1 serostatus, female sex workers and men
having sex with men who are highly exposed to HIV-1. The mechanisms identified or invoked
to modulate susceptibility to infection in the various studies emphasize the relevance of
differences in acquired immunity through the role of protective cytotoxic T-cell responses and
NK activity in the context of specific HLA class I alleles, as well as differences in humoral
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responses at mucosal surfaces58,59. A large study is needed to compare uninfected individuals
with known and quantifiable exposure to HIV-1 with a large cohort of infected individuals that
are carefully matched demographically.
The importance of reliable study phenotypes is intimately linked to the creation of appropriate
cohorts for genetic analysis. Several recommendations for optimal design of genetic-
association studies in clinical trials and cohorts are presented elsewhere3,60–62. Examples of
initiatives that have integrated genetic data for future clinical research are: the Adult AIDS
Clinical Trials Group (AACTG) Protocol A5128 (Ref. 63) and the National Institute of Allergy
and Infectious Diseases (NIAID)-sponsored GENOMICS protocol. Both protocols establish
the conditions for storing DNA for studies that were not planned when informed consent was
provided, and for future analyses.
The two-genome paradigm
The genome of HIV-1 co-evolves with that of the host. This is more pronounced for HIV-1
than for many other human pathogens because of the recognized capacity of retroviruses to
mutate and thereby escape from the immune response and to adapt to the host environment.
The need for continuous evolution for both the host and the pathogen is illustrated by the Red
Queen principle.
At a population level, this host–viral interaction can be detected in several ways. For example,
major histocompatibility complex (MHC)-restricted immune responses might shape viral
genetic diversity over time because the immune selective pressure forces the emergence of
viruses with escape mutations that result in infected cells that are no longer recognized by
cytotoxic T lymphocytes64–67. However, certain host genotypes (for example, HLA-B*57)
have reproducible associations with successful control of HIV-1 viral load68, implying that
these genotypes exert selection pressure on diverse viral populations that are difficult to evade.
The genome of HIV-1 can also be investigated using evolutionary genomics tools to identify
signals of recent positive selection69,70. In the future, genomic approaches might need to
simultaneously address the genome of both the host and the pathogen.
Although here we focus on the host genome, it is important to consider the role of the virus
strain diversity and fitness as an equally important factor in HIV-1 susceptibility and
pathogenesis71,72. The hypervariable nature of retroviruses and the simultaneous presence of
quasispecies in any given patient make the goal of controlling for viral diversity a challenging
one. Biological validation of newly identified host factors will, as a first step, require the use
of a limited set of laboratory or clinical isolates and, increasingly, of data derived from studies
using SIV.
Genomics and HIV-1 vaccine development
Genomics provides many new possibilities for vaccine research. First, previous unsuccessful
vaccine trials can be investigated to identify genetic variants that influenced the magnitude of
an evoked immune response and thereby highlight reasons for their overall failure. For
example, the failed VAXGEN trial included 5,403 HIV-negative volunteers in a randomized,
placebo-controlled trial of a recombinant glycoprotein 120 vaccine73. There were 368 subjects
who acquired infection after vaccination; 6.7% in the vaccine arm of the trail and 7.0% in the
placebo arm The course of HIV-1 infection was comparable between the two groups. However,
the VAXGEN trial reported that titres of neutralizing antibodies in vaccine recipients varied
considerably among participants, therefore constituting a potential target for genome
analysis74. So, host genetic analyses allow revisiting of past vaccine trials for analysis of a
new order of biological endpoints and basic questions. Whole-genome analyses can provide a
unique description of how host genetic variation influences the early stages of HIV-1 infection,
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the exposed and uninfected state, the generation of anti-HIV-1 neutralizing antibodies and the
breadth of cytotoxic T-lymphocyte responses. In addition, comparative and evolutionary
genomics can complement the analysis by pointing to species-specific aspects of disease
susceptibility, in particular through the standardized analysis of the mechanisms of innate
immunity and intrinsic cellular defence.
Some of the challenges and opportunities discussed above are being pursued as part of the
recently funded Center for HIV/AIDS Vaccine Immunology (CHAVI) (Box 2). The host
genetics team at CHAVI is attempting a detailed genetic investigation of the control of the
earlier phases of HIV infection, focusing both on viral load set point and, more ambitiously,
on the control of viral build-up during the acute phase of infection. A key feature of the CHAVI
programme is to use a common genetic platform across multiple cohorts allowing both
replication of associations and a careful assessment of how gene variants function at different
points during infection and subsequent viral dynamics. In addition to the CHAVI genomics
project, another initiative, the HIV Elite Controller Study, will apply genomic techniques to
the investigation of people infected with HIV-1 who have been able to maintain viral loads at
or below the limits of detection. This collaborative study will address the key viral, host genetic
and immunological contributions to this extraordinary outcome of infection. However, data
analysis remains a significant problem: developing analytical routines that are able to deal with
the unprecedented quantity of genomic information will pose a considerable challenge to the
statistical genetics community which, until recently, has been only modestly involved in HIV-1
host genetics studies75.
Conclusions
It is both a scientific and a social priority to apply modern and powerful genomic analyses to
the study of HIV-1 infection and to aid the understanding of other important human pathogens,
such as malaria and tuberculosis. The population geneticist Andrew G. Clark compared these
new ‘discovery sciences’ to the voyage of the HMS Beagle “…setting sail to who knows where,
amassing genome data on our hard drives and pawing through it to discover things that have
not been seen before.”76
Paradoxically, as technical (large-scale genotyping) and analytical issues (genetic statistics)
are progressively solved, the main challenge is posed by the quality of cohorts. Despite 2006
being the 25th anniversary of the first reported case of AIDS, appropriate cohorts remain
surprisingly undeveloped — there are no large acute-infection cohorts and only moderately
sized seroconversion cohorts (limiting replication of data), and an overall lack of preparedness
for genetic work (ethical and legal clearance, and appropriate informed consent for genetic
studies). We should emphasize that it is not technology, but cohorts, that constitute the key
limiting factor today. We believe that the solution to this problem lies in multinational
collaborations to establish and pool cohorts to synergize with efforts such as the Global HIV/
AIDS enterprise that is being spearheaded by the NIH and the Bill and Melinda Gates
Foundation.
Box 1
The HapMap project
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The HapMap project (stands for Haplotype Mapping Project) provides an invaluable
resource for researchers interested in relating human genetic variation to human health by
allowing the selection of polymorphisms that represent other common polymorphisms in
the human genome. These polymorphisms are called tagging single-nucleotide
polymorphisms (tag SNPs) because they ‘tag’ other polymorphisms, which then do not need
to be genotyped (see figure). The aim is to ensure that all the SNPs in the genome are directly
represented by at least one SNP that is included on the analysis chip. Increasingly, this is
being done on a genome-wide scale using standardized sets of tagging SNPs. This aim has
nearly been achieved in current commercially available platforms for whole-genome
association studies, allowing interrogation of most common human polymorphisms either
directly or indirectly through association with tag-SNP candidates. As shown in panel a of
the figure, genotype data (for a gene or a region of interest) are freely available from the
HapMap website. The associations among SNPs in the data are then assessed to select tag
SNPs. In part b of the figure, SNPs (coloured stars), that associate closely with each other
have the same colour. The overall set of SNPs can be represented by a subset of tag SNPs,
depicted in the figure as one star of each colour. Part c of the figure shows subsequent
genetic association analysis. The tag SNPs are genotyped in a population sample in which
individuals vary for the trait of interest, for example, increased susceptibility to HIV-1. A
tag SNP that correlates with resistance to infection indicates that one of the known or
unknown SNPs with which it is associated (black lollipops) might influence this phenotype
— in this case, the non-genotyped SNP might be responsible for the association of the blue
and green tag SNPs with resistance to HIV-1, shown by the corresponding high P values.
From the set of SNPs that were not genotyped as tags, those in exons 2 and 3 are good
candidates (coloured arrows depict a high linkage disequilibrium). Text and figure modified
with permission from Nature Ref. 13 (2005) Macmillan Publishers Ltd.
Box 2
The CHAVI genome initiative
The Center for HIV-AIDS Vaccine Immunology (CHAVI; see Further information) is a
significant component of the Global HIV Vaccine Enterprise77. Based at Duke University
in Durham, USA, it includes investigators from institutions across the globe. CHAVI has
included genomics as a core project in the quest for a vaccine against HIV-1. The genome
initiative includes the establishment of a series of cohorts with appropriate phenotypes. The
first target phenotype is the viral load at set point in individuals with a known date of
seroconversion. There is the potential to study between 1,000 and 2,000 qualifying patients
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across different cohorts. CHAVI will progressively focus on the study of at least 2,000
exposed individuals that will include infected and non-infected individuals from several
clinical sites in Africa. This study aims to identify genetic determinants of protection from
infection. Genotyping will be done using chips designed explicitly for whole-genome
association studies. These chips allow genotyping of polymorphisms that represent common
variation in the populations studied in the HapMap project: 550,000 single nucleotide
polymorphisms (SNPs) for the study of subjects of European ancestry, and approximately
650,000 SNPs in subjects of African ancestry to reflect the lower level of linkage
disequilibrium in Africa.
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Glossary
Comparative genomics 
The study of relationships among the genomes of different species.
Evolutionary genomics 
The study of how changes in the content and organization of genomes have
contributed to the diversity of life and the pressures that have shaped genomes.
Comparative and evolutionary genomics identify signatures of selection that can
often identify functional structures of sequence that are not otherwise easily
annotated.
Haplotype  
Stands for haploid genotype — a collection of single nucleotide polymorphisms
(SNPs) in one chromosome that tend to occur together (that is are linked) in
individuals.
Linkage analysis 
Genes that lie close to each other on a chromosome tend to be inherited together.
Markers on this segment of the chromosome can therefore be used for tracking
the gene associated with a study phenotype.
Linkage disequilibrium 
The condition in which the haplotype frequencies in a population deviate from
the values they would have if the allelic variants at each locus were combined at
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random. In this situation the allele present at one locus can be used to predict the
allele present at another and both alleles need not be typed in an association study.
Negative selection 
Also known as purifying selection. Occurs when natural selection results in the
removal of alleles that are deleterious. This can result in conserved gene
sequences being maintained between species over long periods of evolutionary
time. Evolutionary analyses identify signs of positive or negative selection by
estimating the rates of substitutions leading to an amino-acid change (non-
synonymous), versus substitutions that do not result in a change of the amino-
acid residue (synonymous change).
Population differentiation 
If two populations are separated from each other then the allele frequencies at a
locus in the two populations might differ because of random drift and/or
differential selection in the two environments.
Positive selection 
This occurs when natural selection favours a single allele and consequently the
frequency of an allele at a genetic locus increases until it is fixed in the entire
population.
Red Queen principle 
The interaction between host and parasite leads to a constant evolutionary process
of adaptation and counter-adaptation. In Lewis Carroll's Through the looking
glass the Red Queen tells Alice that “It takes all the running you do to keep in
the same place.”
SNP  
Pronounced ‘snip’. Stands for single nucleotide polymorphism which is a DNA
sequence variation that arises when a single nucleotide (A, T, C or G) in the
genome sequence differs among members of the species.
Stratification 
If a cohort includes individuals from different subgroups or populations then
spurious association will be identified for any marker showing allele frequency
differences between the (unknown) subgroups if the phenotype of interest has a
different incidence between the subgroups. This phenomenon is called
stratification and is thought to contribute to many false-positive findings in the
complex-trait literature.
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Figure 1. Whole-genome association analysis strategy
The figure shows the steps needed to define a study phenotype and genotype, and the
downstream procedures used to prioritize candidate genes to be investigated by genetic and
functional approaches. The study phenotype(s) should be robust, that is, consistent, and should
represent a characteristic of the individual that can be measured precisely. Examples include
susceptibility to infection or viral load set point. Genotyping should take into consideration
the specific population studied, as the number of polymorphic markers (single-nucleotide
polymorphisms; SNPs) that require analysis differs for African or non-African populations.
After the identification of genetic markers that are associated with the phenotype, a
comprehensive bioinformatics and genetic analysis of the genomic region is done to identify
causal candidate variants associated with the marker. Also, replication studies in other human
cohorts, analysis in the context of other HIV-1 infection endpoints or phenotypes, and dedicated
biological studies dictated by the nature of the genes that are mapped and their plausible
mechanism of action are used to prioritize appropriate candidate genes.
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Figure 2. Comparative and evolutionary analysis of host proteins involved in HIV-1 pathogenesis
This analysis used a comprehensive set of sequences that are representative of the primate
lineages — new world monkeys, old world monkeys, gibbons and apes — to identify signs of
positive and of negative selection in protein domains. The three proteins depicted represent
different patterns of evolution in primates. The antiretroviral protein APOBEC3G is
characterized by many residues that are under positive selective pressure, with a large cluster
that delineates the virion infectivity factor (Vif)-interaction domain. These amino acids
contribute to discrimination among the various Vif proteins of HIV and different SIVs. A
second antiretroviral protein, TRIM5α (tripartite motif 5α) has a patch of positively selected
residues that defines the variable 1 region (v1) and variable 2 region (v2) and that carry the
capsid recognition specificity. The variable regions of TRIM5α might have evolved
independently to recognize various retroviruses. By contrast, there are no residues under
positive selective pressure in the PML/TRIM19 protein, which is also proposed to have
antiviral properties. Therefore, the effect of PML/TRIM19 might be indirect. Failure to identify
a signature of positive selection militates against a more direct role for this protein in antiviral
defence, because it would be expected that prolonged contact with several pathogens over long
evolutionary time periods would have resulted in signatures of positive selection indicative of
a genetic conflict. Bars represent amino acids that are predicted to be under positive selection
in a grading of posterior probability from 0 to 1. The various protein domains are indicated.
Adapted with permission from Ref. 31.
Telenti and Goldstein Page 16
Nat Rev Microbiol. Author manuscript; available in PMC 2007 October 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3. The viral load set point
a | Soon after infection, HIV replicates to high levels (peak viraemia). Host factors then exert
their effects to limit viral replication to a post-acute set-point level of plasma viraemia. b | The
dynamics of establishment of the viral load set point in an individual presenting with HIV
primary infection are shown. c | Viraemia data from three individuals are shown, characterized
by post-acute viral load set points at 5, 3 and <2 log10 HIV-1 RNA copies per millilitre — fully
stable over 3 years. Without these reliable patterns of inter-individual variation, genetics would
have little to contribute to the analysis of viral load set point.
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s, 
po
pu
la
tio
ns
 a
nd
 c
on
se
ns
us
3,
78
.
* P
ro
po
se
d 
gr
ad
in
g 
of
 g
en
et
ic
 a
nd
 m
ol
ec
ul
ar
 e
vi
de
nc
e:
 th
e 
de
gr
ee
 o
f e
vi
de
nc
e 
is
 in
di
ca
te
d 
fr
om
 1
 (w
ea
k 
ev
id
en
ce
) t
o 
3 
(s
tro
ng
 e
vi
de
nc
e)
. T
he
 a
ss
es
sm
en
t r
ef
le
ct
s t
he
 in
te
rp
re
ta
tio
n 
of
 th
e 
au
th
or
s o
f
an
 u
ne
qu
al
 b
od
y 
of
 e
vi
de
nc
e.
 T
he
 g
ra
di
ng
 o
f g
en
et
ic
 a
nd
 m
ol
ec
ul
ar
 e
vi
de
nc
e 
fo
llo
w
s t
he
 p
ro
po
sa
l b
y 
J. 
P.
 Io
an
ni
di
s1
.
‡ E
ff
ec
t s
iz
e:
 0
, g
en
er
al
 c
on
se
ns
us
 fo
r n
o 
ef
fe
ct
; 1
, v
er
y 
sm
al
l o
r s
m
al
l e
ff
ec
t s
iz
e 
(r
el
at
iv
e 
ris
k 
2)
; 2
, m
od
er
at
e 
ef
fe
ct
 si
ze
 (r
el
at
iv
e 
ris
k 
2–
5)
; 3
, l
ar
ge
 e
ff
ec
t s
iz
e 
(r
el
at
iv
e 
ris
k 
5)
.
§ A
m
ou
nt
 a
nd
 re
pl
ic
at
io
n 
of
 e
vi
de
nc
e:
 1
, s
in
gl
e 
or
 fe
w
 sc
at
te
re
d 
st
ud
ie
s;
 2
, m
et
a-
an
al
ys
es
 o
f g
ro
up
 d
at
a;
 3
, l
ar
ge
-s
ca
le
 e
vi
de
nc
e 
fr
om
 in
cl
us
iv
e 
ne
tw
or
ks
.
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∥ Pr
ot
ec
tio
n 
fr
om
 b
ia
s:
 1
, c
le
ar
 p
re
se
nc
e 
of
 st
ro
ng
 b
ia
s i
n 
th
e 
ev
id
en
ce
; 2
, u
nc
er
ta
in
 a
bo
ut
 th
e 
pr
es
en
ce
 o
f b
ia
s;
 3
, c
le
ar
 st
ro
ng
 p
ro
te
ct
io
n 
fr
om
 b
ia
s.
¶ B
io
lo
gi
ca
l c
re
di
bi
lit
y:
 1
, n
o 
fu
nc
tio
na
l/b
io
lo
gi
ca
l d
at
a 
or
 n
eg
at
iv
e 
da
ta
; 2
, l
im
ite
d 
or
 c
on
tro
ve
rs
ia
l f
un
ct
io
na
l/b
io
lo
gi
ca
l d
at
a;
 3
, c
on
vi
nc
in
g 
fu
nc
tio
na
l/b
io
lo
gi
ca
l d
at
a.
**
R
el
ev
an
ce
: 1
, n
o 
cl
in
ic
al
 o
r p
ub
lic
 h
ea
lth
 a
pp
lic
ab
ili
ty
; 2
, l
im
ite
d 
cl
in
ic
al
 o
r p
ub
lic
 h
ea
lth
 a
pp
lic
ab
ili
ty
; 3
, c
on
si
de
ra
bl
e 
cl
in
ic
al
/p
ub
lic
 h
ea
lth
 a
pp
lic
ab
ili
ty
. L
im
ite
d 
or
 in
su
ff
ic
ie
nt
 d
at
a 
fo
r: 
C
XC
R6
,
C
C
L4
L,
 C
C
L2
 (M
C
P1
) C
C
L7
, C
C
L1
, I
FN
G
, L
TA
 (T
N
Fβ
), 
IL
4R
, I
L2
R,
 IL
10
R,
 D
EF
B1
, C
D
20
9 
(D
C
-S
IG
N
), 
D
C
-S
IG
N
R,
 M
BL
2,
 P
TP
RC
, S
LC
11
A1
 (N
RA
M
P1
), 
VD
R,
 P
PI
A,
 P
M
L,
 T
N
FR
SF
1A
,
βT
RC
, I
N
I1
, N
AF
1,
 H
P6
8,
 Y
Y1
, A
IP
1/
AL
IX
, T
AP
, C
TL
A4
 a
nd
 P
RF
1.
 M
H
C
, m
aj
or
 h
is
to
co
m
pa
tib
ili
ty
 c
om
pl
ex
; N
K
, n
at
ur
al
 k
ill
er
 c
el
ls
; N
-M
LV
, N
-m
ur
in
e 
le
uk
ae
m
ia
 v
iru
s;
 U
TR
, u
nt
ra
ns
la
te
d 
re
gi
on
.
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